Nalbuphine and Paraesthesia - a phase IV clinical study of FDA data

Summary:

Paraesthesia is reported as a side effect among people who take Nalbuphine (nalbuphine hydrochloride), especially for people who are female, 10-19 old, have been taking the drug for < 1 month also take Lorazepam, and have Drug dependence.

The phase IV clinical study analyzes which people have Paraesthesia when taking Nalbuphine. It is created by eHealthMe based on reports of 1,089 people who have side effects when taking Nalbuphine from the FDA, and is updated regularly.

What is Nalbuphine?

Nalbuphine has active ingredients of nalbuphine hydrochloride. eHealthMe is studying from 1,091 Nalbuphine users. Check the latest studies of Nalbuphine.

What is Paraesthesia?

Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect) is found to be associated with 2,689 drugs and 3,121 conditions by eHealthMe. Check the latest studies of Paraesthesia.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

1,089 people reported to have side effects when taking Nalbuphine.
Among them, 15 people (1.38%) have Paraesthesia.

Among these 15 people:

How long have people been on Nalbuphine when they have Paraesthesia? *

What is the gender of people who have Paraesthesia when taking Nalbuphine? *

female: 87.5 %
male: 12.5 %

What is the age of people who have Paraesthesia when taking Nalbuphine? *

What are other drugs people take besides Nalbuphine? *

What are other side effects people have besides Paraesthesia? *

Stress And Anxiety: 10 people, 66.67%
Osteomyelitis (infection of bone): 8 people, 53.33%
Metastases To Bone (cancer spreads to bone): 8 people, 53.33%
Weight Decreased: 7 people, 46.67%
Device Related Infection: 7 people, 46.67%
Right Atrial Dilatation (enlargement of the right atrium chamber of heart): 7 people, 46.67%
Neuropathy Peripheral (surface nerve damage): 7 people, 46.67%
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets): 7 people, 46.67%
Fever: 7 people, 46.67%
Dyspnea (difficult or laboured breathing): 7 people, 46.67%

What are the existing conditions these people have? *

Drug Dependence: 7 people, 46.67%
T-Cell Type Acute Leukaemia (a form of cancer of the white blood cells): 3 people, 20.00%
Birth Control: 2 people, 13.33%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 6.67%
Metastases To Bone (cancer spreads to bone): 1 person, 6.67%
Breast Cancer Female: 1 person, 6.67%
Breast Cancer: 1 person, 6.67%
Bipolar I Disorder (mood disorder that is characterized by at least one manic or mixed episode): 1 person, 6.67%
Acne (skin problems that cause pimples): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Nalbuphine and have Paraesthesia?

- Check whether Paraesthesia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Nalbuphine:

Nalbuphine (1,091 reports)

Paraesthesia treatments and more:

Paraesthesia (184,215 reports)

Browse all side effects of Nalbuphine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Paraesthesia:

Paraesthesia (2,689 drugs)

Browse all the conditions that are associated with Paraesthesia:

Paraesthesia (3,121 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on nalbuphine hydrochloride (the active ingredients of Nalbuphine) and Nalbuphine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.